Preferred Label : R-HyperCVAD Alternating with High-dose MTX AraC/Rituximab Regimen;
NCIt synonyms : R-hyperCVAD Alternating with R-Methotrexate-Cytarabine; Rituximab Plus HyperCVAD Alternating with Rituximab-Methotrexate/Cytarabine; Rituximab Plus Hyper-CVAD Alternating with R-Methotrexate/Cytarabine; R-HCVAD Plus Methotrexate/Cytarabine; R-HyperCVAD/MTX/AraC; Rituximab Plus HyperCVAD Alternating with Rituximab Plus High-dose Cytarabine and
Methotrexate; Rituximab Plus HyperCVAD Alternating with R-Methotrexate/Cytarabine; Rituximab-Hyperfractionated Cyclophosphamide-Vincristine-Adriamycin-Dexamethasone
Alternating with Rituximab/Cytarabine/Methotrexate; R-HyperCVAD/HD MTX AraC Regimen;
NCIt related terms : R-HyperCVAD Alternating with High-dose MTX AraC Regimen; R-Hyper-CVAD/R-MA; R-Hyper-CVAD/R-MA (rituximab-abbs); R-Hyper-CVAD/R-MA (rituximab-pvvr); R-Hyper-CVAD/R-MA (rituximab-rixa); R-Hyper-CVAD/R-MA (rituximab-rite); R-Hyper-CVAD/R-MA (rituximab-rixi); R-Hyper-CVAD/R-MA (rituximab-blit); R-Hyper-CVAD/R-MA (rituximab-arrx);
NCIt definition : A regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin and
dexamethasone, administered on a hyperfractionated schedule, and alternating with
rituximab, and high-dose methotrexate and cytarabine that can be used for the treatment
of mantle cell lymphoma (MCL), AIDS-related B-cell lymphomas, Burkitt lymphoma, chronic
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), diffuse large B-cell
lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), and T-cell lymphoma.;
NCI Metathesaurus CUI : CL538294;
Codes from synonyms : 4573; 128033; 128190; 127719; 128347; 127876; 128504; 128661;
Origin ID : C140115;
UMLS CUI : C4682710;
Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
